Heartseed
- Biotech or pharma, therapeutic R&D
Heartseed is a Japanese public biotech (Sec code: 219A, Market Cap is around $400M) developing cardac replacement theraly for heart failure under collaboration with Novo Nordisk. We completed the enrolloment of Ph1/2 clinical trial in Japan in early 2025 and waiting for the data readouts. We are interested in in-licensing and investment opportunities to broaden our portfolio in particular cardiovasular space and new modalities.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}